调脂颗粒治疗激素受体阳性绝经后乳腺癌患者临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R273

基金项目:

浙江省中医药科技计划项目(2024ZL1181)


Clinical Study on Tiaozhi Granules for Hormone Receptor-Positive Postmenopausal Breast Cancer Patients
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察调脂颗粒对服用来曲唑治疗的激素受体阳性绝经后乳腺癌湿浊血瘀证患者血脂、免疫 功能、性激素等指标的影响。方法:选取2023年1月—2024年4月于浙江大学医学院附属金华医院治疗的60例 激素受体阳性绝经后乳腺癌湿浊血瘀证患者,按随机数字表法分为对照组和治疗组各30例。2组均予来曲唑治 疗,治疗组加用调脂颗粒,2组均治疗12周。治疗前后检测2组患者的血脂指标包括总胆固醇(TC)、甘油三酯 (TG)、高密度脂蛋白胆固醇 (HDL-C)、低密度脂蛋白胆固醇 (LDL-C)、脂蛋白 (a)[Lp (a)]、载脂蛋 白A (Apo A)、载脂蛋白B(Apo B),T淋巴细胞亚群指标(CD3 + 、CD4 + 、CD8 + 、CD4 + /CD8 + )、性激素[促黄 体生成素 (LH)、促卵泡生成素 (FSH)、雌二醇 (E2)]、肿瘤指标 [癌胚抗原 (CEA)、糖类抗原 125 (CA125)、糖类抗原 153 (CA153)]、肝肾功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶 (ALP)、γ-谷氨酰转移酶 (γ-GT)、血肌酐 (SCr)、血尿素氮 (BUN)]。结果:治疗后,2组 TC、Lp (a)、 Apo B水平均较治疗前升高 (P<0.05)。对照组Apo A水平较治疗前下降 (P<0.05),LDL-C水平较治疗前升 高(P<0.05)。治疗组TC、LDL-C、Lp(a)、Apo B水平均低于对照组(P<0.05),HDL-C、Apo A水平均高 于对照组(P<0.05)。治疗组CD3 + 、CD4 + 水平均较治疗前升高(P<0.05),CD3 + 水平高于对照组(P<0.05)。 2组治疗前后的性激素指标、肿瘤标志物、肝肾功能指标分别比较,差异均无统计学意义(P>0.05)。结论:调 脂颗粒能够有效改善服用来曲唑治疗的激素受体阳性绝经后乳腺癌湿浊血瘀证患者的血脂情况,提高其免疫功 能,且安全性较好。

    Abstract:

    Abstract:Objective:To observe the effects of Tiaozhi Granules on blood lipids,immune function,and sex hormones in hormone receptor-positive postmenopausal breast cancer patients with damp-turbidity and blood stasis syndrome treated with Letrozole. Methods:A total of 60 cases of hormone receptor-positive postmenopausal breast cancer patients with damp-turbidity and blood stasis syndrome,who treated at Jinhua Hospital Affiliated to Zhejiang University School of Medicine from January 2023 to April 2024,were selected and divided into the control group and the treatment group according to the random number table method,with 30 cases in each group. Both groups received Letrozole as adjuvant endocrine therapy,and the treatment group was additionally treated with Tiaozhi Granules based on the treatment of the control group. Both groups were treated for 12 weeks. Blood lipid indicators including total cholesterol(TC), triglycerides(TG), high-density lipoprotein cholesterol(HDL -C), low-density lipoprotein cholesterol(LDL-C),lipoprotein(a)Lp(a),apolipoprotein A(Apo A),apolipoprotein B(Apo B),T lymphocyte subsets(CD3 + ,CD4 + ,CD8 + ,CD4 + /CD8 + ),sex hormones [luteinizing hormone(LH),follicle-stimulating hormone (FSH), estradiol(E2)], tumor markers [carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125), carbohydrate antigen 153(CA153)], and liver and kidney function indicators [alanine aminotransferase (ALT), aspartateaminotransferase(AST),alkalinephosphatase(ALP),γ-glutamyltransferase(γ-GT),serumcreatinine(SCr), blood urea nitrogen(BUN)] in the two groups were measured before and after treatment. Results:After treatment,the levels of TC,Lp(a),and Apo B in the two groups were increased when compared with those before treatment(P< 0.05). The Apo A level in the control group was decreased when compared with that before treatment(P<0.05)and LDL-C level was increased when compared with that before treatment(P<0.05). The levels of TC,LDL-C,Lp(a), and Apo B in the treatment group were lower than those in the control group(P<0.05),and the levels of HDL-C and Apo A were higher(P<0.05). The levels of CD3 + and CD4 + in the treatment group were increased when compared with those before treatment(P<0.05),the level of CD3 + in the treatment group was higher than that in the control group (P<0.05). There were no significant differences in the comparison of sex hormone indicators,tumor markers,or liver and kidney function indicators between the two groups before and after treatment(P>0.05). Conclusion:Tiaozhi Granules can effectively improve blood lipid profiles and enhance immune function in hormone receptor-positive postmenopausal breast cancer patients with damp-turbidity and blood stasis syndrome treated with Letrozole,and the treatment is relatively safe.

    参考文献
    相似文献
    引证文献
引用本文

任连杰,陶飞宝,李剑霜,范逸群.调脂颗粒治疗激素受体阳性绝经后乳腺癌患者临床研究[J].新中医,2025,57(16):120-125

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-08-26
  • 出版日期:
文章二维码